Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 5 art units • 5 examiners • 0 of 6 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Nacuity Pharmaceuticals Inc. currently has 6 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 6 actions are being handled by 5 distinct examiners, which indicates that nearly every pending matter is being reviewed by a different individual. The portfolio is also distributed across 5 distinct art units, suggesting that the company's Biotechnology & Pharmaceuticals applications are evaluated by several specialized technical groups within the patent office.
The busiest examiner for the portfolio is Bonaparte, Amy C, who is responsible for 2 of the pending office actions. Since Bonaparte, Amy C manages 2 out of the 6 total actions, this examiner's specific feedback and requirements will be a factor in the company's current prosecution efforts. The 5 distinct art units involved mean that the 6 pending office actions are subject to the specific guidelines of five different examination groups, requiring a tailored approach for each case.
Practitioners managing these 6 pending office actions must prioritize the relationship with Bonaparte, Amy C, given their oversight of 2 cases. The presence of 5 distinct examiners and 5 distinct art units for 6 actions shows that the portfolio is distributed across multiple procedural silos. This distribution requires a strategy that addresses the specific technical nuances of each Biotechnology & Pharmaceuticals art unit while managing the influence of the busiest examiner on the overall portfolio.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (33%) |
| Double-patenting + other | 1 (17%) |
| Multi-statute (no §101) | 3 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BONAPARTE, AMY C | 2 | 79.3% | +23.2% |
| KIM, DANIELLE A | 1 | 37.1% | +56.3% |
| KASSA, TIGABU | 1 | 36.7% | +27.9% |
| CHONG, YONG SOO | 1 | 43.8% | +41.6% |
| KWON, JOHN SEUNGJAI | 1 | 45.7% | +19.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18770850 | METHOD FOR PREPARATION OF N-ACETYL CYSTEINE AMIDE OR DI- N-ACETYL CYSTEINE AMIDE AND DERIVATIVES | BONAPARTE, AMY C | 14d |
| 18678550 | METHOD FOR PREPARATION OF N-ACETYL CYSTEINE AMIDE OR DI- N-ACETYL CYSTEINE AMIDE AND DERIVATIVES | BONAPARTE, AMY C | 14d |
| 19173475 | METHOD FOR PREPARATION OF N-ACETYL CYSTEINE AMIDE, DERIVATIVES AND TABLETS THEREOF | KASSA, TIGABU | 40d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18770850 | METHOD FOR PREPARATION OF N-ACETYL CYSTEINE AMIDE OR DI- N-ACETYL CYSTEINE AMIDE AND DERIVATIVES | BONAPARTE, AMY C | 14d |
| 18678550 | METHOD FOR PREPARATION OF N-ACETYL CYSTEINE AMIDE OR DI- N-ACETYL CYSTEINE AMIDE AND DERIVATIVES | BONAPARTE, AMY C | 14d |
| 19173475 | METHOD FOR PREPARATION OF N-ACETYL CYSTEINE AMIDE, DERIVATIVES AND TABLETS THEREOF | KASSA, TIGABU | 40d |
| 17701051 | TREATMENT OF FERROPTOSIS | CHONG, YONG SOO | 60d |
| 19539174 | METHOD FOR PREPARATION OF N-ACETYL CYSTEINE AMIDE AND DERIVATIVES THEREOF, AND TABLETS THEREOF | KIM, DANIELLE A | — |
| 17339652 | TREATMENT OF CYSTINOSIS | KWON, JOHN SEUNGJAI | — |
| Art Unit | Apps |
|---|---|
| 1692 | 2 |
| 1613 | 1 |
| 1619 | 1 |
| 1623 | 1 |
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19539174 | METHOD FOR PREPARATION OF N-ACETYL CYSTEINE AMIDE AND DERIVATIVES THEREOF, AND TABLETS THEREOF | KIM, DANIELLE A | 1613 | §103§112DP | Non-Final OA | — | Pending | Feb 13, 2026 |
| 19173475 | METHOD FOR PREPARATION OF N-ACETYL CYSTEINE AMIDE, DERIVATIVES AND TABLETS THEREOF | KASSA, TIGABU | 1619 | §103§112 | Non-Final OA | 40d | Pending | Apr 08, 2025 |
| 18770850 | METHOD FOR PREPARATION OF N-ACETYL CYSTEINE AMIDE OR DI- N-ACETYL CYSTEINE AMIDE AND DERIVATIVES | BONAPARTE, AMY C | 1692 | §102§103 | Non-Final OA | 14d | Pending | Jul 12, 2024 |
| 18678550 | METHOD FOR PREPARATION OF N-ACETYL CYSTEINE AMIDE OR DI- N-ACETYL CYSTEINE AMIDE AND DERIVATIVES | BONAPARTE, AMY C | 1692 | §102§103 | Non-Final OA | 14d | Pending | May 30, 2024 |
| 17701051 | TREATMENT OF FERROPTOSIS | CHONG, YONG SOO | 1623 | §103 | Final Rejection | 60d | Pending | Mar 22, 2022 |
| 17339652 | TREATMENT OF CYSTINOSIS | KWON, JOHN SEUNGJAI | 1615 | §103 | Non-Final OA | — | Pending | Jun 04, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial